Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders Equity

v3.19.3
Consolidated Statements of Stockholders Equity - USD ($)
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Total
Balance at Dec. 31, 2017   $ 4,000 $ 192,670,000 $ (194,170,000) $ (1,914,000) $ (3,410,000)
Balance (in shares) at Dec. 31, 2017   3,671,014        
Stock-based compensation $ 0 $ 0 676,000 0 0 676,000
Fair Value of Warrants issued 0 0 9,000 0 0 9,000
Series A Preferred Stock Dividends 0 0 0 (59,000) 0 (59,000)
Net loss $ 0 0 0 (2,316,000) 0 (2,316,000)
Non-controlling interest   0 0 0 (9,000) (9,000)
Balance at Mar. 31, 2018   $ 4,000 193,355,000 (196,545,000) (1,923,000) (5,109,000)
Balance (in shares) at Mar. 31, 2018   3,671,014        
Balance at Dec. 31, 2017   $ 4,000 192,670,000 (194,170,000) (1,914,000) (3,410,000)
Balance (in shares) at Dec. 31, 2017   3,671,014        
Net loss           (10,194,000)
Non-controlling interest           (35,000)
Balance at Sep. 30, 2018   $ 5,000 200,807,000 (204,545,000) (1,948,000) (5,681,000)
Balance (in shares) at Sep. 30, 2018   5,349,002        
Balance at Mar. 31, 2018   $ 4,000 193,355,000 (196,545,000) (1,923,000) (5,109,000)
Balance (in shares) at Mar. 31, 2018   3,671,014        
Stock-based compensation     557,000     557,000
Series A Preferred Stock Dividends       (61,000)   (61,000)
Stock issued under "at-the-market" offering     400,000     400,000
Stock issued under "at-the-market" offering (in shares) 0 49,490        
Net loss       (4,198,000)   (4,198,000)
Non-controlling interest         (16,000) (16,000)
Balance at Jun. 30, 2018   $ 4,000 194,312,000 (200,804,000) (1,939,000) (8,427,000)
Balance (in shares) at Jun. 30, 2018   3,720,504        
Stock-based compensation     475,000     475,000
Series A Preferred Stock Dividends       (61,000)   (61,000)
Stock issued under "at-the-market" offering   $ 1,000 6,020,000     6,021,000
Stock issued under "at-the-market" offering (in shares)   1,628,498        
Net loss       (3,680,000)   (3,680,000)
Non-controlling interest         (9,000) (9,000)
Balance at Sep. 30, 2018   $ 5,000 200,807,000 (204,545,000) (1,948,000) (5,681,000)
Balance (in shares) at Sep. 30, 2018   5,349,002        
Balance at Dec. 31, 2018 $ 5,760,000 $ 15,000 230,754,000 (219,461,000) (2,909,000) 14,159,000
Balance (in shares) at Dec. 31, 2018 9,161 15,482,083        
Stock-based compensation $ 0 $ 0 64,000 0 0 64,000
Series A Preferred Stock Dividends 0 0 0 (61,000) 0 (61,000)
Issuance of SYN Biomics Stock 0 0 (36,000) 0 53,000 17,000
Conversion of Series B Preferred Stock to Common $ (638,000) $ 1,000 1,035,000 (398,000) 0 0
Conversion of Series B Preferred Stock to Common (in shares) (1,036) 900,869        
Net loss $ 0 $ 0 0 (3,512,000) 0 (3,512,000)
Non-controlling interest   0 0 0 (16,000) (16,000)
Balance at Mar. 31, 2019 $ 5,122,000 $ 16,000 231,817,000 (223,432,000) (2,872,000) 10,651,000
Balance (in shares) at Mar. 31, 2019 8,125 16,382,952        
Balance at Dec. 31, 2018 $ 5,760,000 $ 15,000 230,754,000 (219,461,000) (2,909,000) 14,159,000
Balance (in shares) at Dec. 31, 2018 9,161 15,482,083        
Net loss           (12,163,000)
Non-controlling interest           (73,000)
Balance at Sep. 30, 2019 $ 4,822,000 $ 17,000 232,485,000 (232,394,000) (2,841,000) 2,089,000
Balance (in shares) at Sep. 30, 2019 7,638 16,806,430        
Balance at Mar. 31, 2019 $ 5,122,000 $ 16,000 231,817,000 (223,432,000) (2,872,000) 10,651,000
Balance (in shares) at Mar. 31, 2019 8,125 16,382,952        
Stock-based compensation $ 0 $ 0 91,000 0 0 91,000
Series A Preferred Stock Dividends 0 0 0 (61,000) 0 (61,000)
Issuance of SYN Biomics Stock 0 0 0 0 45,000 45,000
Conversion of Series B Preferred Stock to Common $ (187,000) $ 1,000 303,000 (117,000) 0 0
Conversion of Series B Preferred Stock to Common (in shares) (302) 262,608        
Net loss   $ 0 0 (3,531,000) 0 (3,531,000)
Non-controlling interest   0 0 0 (27,000) (27,000)
Balance at Jun. 30, 2019 $ 4,935,000 $ 17,000 232,211,000 (227,141,000) (2,854,000) 7,168,000
Balance (in shares) at Jun. 30, 2019 7,823 16,645,560        
Stock-based compensation $ 0 $ 0 91,000 0 0 91,000
Series A Preferred Stock Dividends 0 0 0 (63,000) 0 (63,000)
Issuance of SYN Biomics Stock 0 0 0 0 43,000 43,000
Conversion of Series B Preferred Stock to Common $ (113,000) $ 0 183,000 (70,000) 0 0
Conversion of Series B Preferred Stock to Common (in shares) (185) 160,870        
Net loss $ 0 $ 0 0 (5,120,000) 0 (5,120,000)
Non-controlling interest 0 0 0 0 (30,000) (30,000)
Balance at Sep. 30, 2019 $ 4,822,000 $ 17,000 $ 232,485,000 $ (232,394,000) $ (2,841,000) $ 2,089,000
Balance (in shares) at Sep. 30, 2019 7,638 16,806,430